• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

Establishment of Immune Biobank for Vaccine Immunogenicity Prediction Using In Vitro and In Silico Methods Against Porcine Reproductive and Respiratory Syndrome Virus

by Elena Iemma | Oct 14, 2025

Poster: T cell Epitope Content Comparison (EpiCC) of swine H1 influenza A virus hemagglutinin to identify best vaccine match

by Elena Iemma | Jan 8, 2024

Poster: iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

Poster: iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

by Elena Iemma | Sep 22, 2023

Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach

by Elena Iemma | May 25, 2023

Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach
H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

by Elena Iemma | Oct 26, 2022

« Older Entries

Recent Posts

  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • Keeping Tolerance in Focus: Treg Control of ADA Depends on Clinical Context
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.